A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer

Inclusion Criteria

• •Cohort 1
• •Age ≥18 years
• •Biopsy-proven PDAC
• •Radiological evidence and clinical assessment that patient has active disease (local, locally advanced, or metastatic)
• •Willing and able to comply with the requirements of the protocol
• •Willing to use their bluetooth-enabled wifi or cellular mobile device
• •Hemoglobin A1c (HbA1c) \> 7%, or fructosamine \> 287 mg/dL, or random glucose \> 180 mg/dL, or strong clinical suspicion that patient has hyperglycemia, making it reasonable to expect their mean daily glucose is ≥154 mg/dL
• •Eastern Cooperative Oncology Group performance status ≤2
• •BMI \<30 kg/m2
• •Cohort 2a
• •Age ≥18 years
• •Biopsy-proven PDAC
• •Radiological evidence and clinical assessment that patient has active disease (local, locally advanced, or metastatic pancreatic cancer)
• •Clinical diagnosis of diabetes mellitus
• •Active care at MSK (defined as at least 1 physician or APP encounter every 3 months) for PDAC during the period from which data were recorded in the electronic medical record (in this retrospective study patients need not be under active care at the time the research is conducted)
• •At least 1 electronic prescription for a sulfonylurea (glipizide, glimepiride, or glyburide) or metformin
• •Three-month baseline period before metformin or sulfonylurea initiation in which the participant does not receive either drug class or insulin
• •Body weight recorded within 3 months before start of metformin or a sulfonylurea
• •Cohort 2b
• •Age ≥18 years
• •Biopsy-proven PDAC
• •Radiological evidence and clinical assessment that patient has active disease (local, locally advanced, or metastatic)
• •Active care at MSK (defined as at least 1 physician or APP encounter every 3 months) for PDAC during the period of data collection
• •Apparent current use based on chart review of metformin (but not sulfonylurea); sulfonylurea (but not metformin); or neither drug